Corporate Banner
Satellite Banner
Molecular & Clinical Diagnostics
Scientific Community
Become a Member | Sign in
Home>News>This Article

Advanced Cell Diagnostics, Leica Biosystems Co-marketing Agreement

Published: Wednesday, August 13, 2014
Last Updated: Wednesday, August 13, 2014
Bookmark and Share
The agreement provides researchers with an integrated and fully automated ISH solution.

Leica Biosystems and Advanced Cell Diagnostics, Inc. have announced the co-marketing of ACD's RNAscope® LS ISH assays with Leica Biosystems' BOND RX research staining platform*. This agreement provides researchers with an integrated and fully automated ISH solution. The market-leading RNAscope LS reagent kits and ISH probes are available from ACD while the BOND RX instrument and associated reagents are supplied by Leica Biosystems.

ACD's RNAscope assays represent a major technological advance for in situ RNA detection. For the first time, robust single RNA molecule detection is available for formalin-fixed, paraffin-embedded (FFPE) tissue. Since their commercialization three years ago, these assays have been adopted across the globe by major pharma biotech companies and leading research institutions for drug discovery, translational research, and the development of clinical and companion diagnostic tests. The RNAscope LS assays are fully automated on the BOND RX platform. This open and flexible system automates staining to provide a fast, high-throughput workflow with exceptional consistency and minimal hands-on time.

"Automation is essential for pharma, biotech, translational labs and academic institutions to apply the RNA ISH technology to a wide range of biomarker analysis applications." said Dr. Yuling Luo, President and CEO of ACD. "We are very pleased to work with Leica Biosystems to expand our automated RNAscope solutions in response to the needs of our rapidly growing customer base."

Dr. David Atkins, VP Advanced Staining at Leica Biosystems added: “Leica is excited to announce the availability of ACD's RNAscope Assays fully automated on the BOND RX. This is another example of how, with its openness and flexibility, the BOND RX is providing researchers with enhanced tools to help speed-up important discoveries and improve cancer diagnostics".

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Scientific News
Mathematical Model Forecasts the Path of Breast Cancer
Chances of survival depend on which organs breast cancer tumors colonize first.
Measuring microRNAs in Blood to Speed Cancer Detection
A simple, ultrasensitive microRNA sensor holds promise for the design of new diagnostic strategies and, potentially, for the prognosis and treatment of pancreatic and other cancers.
Biomedical Imaging at One-Thousandth the Cost
Mathematical modeling enables $100 depth sensor to approximate the measurements of a $100,000 piece of lab equipment.
Improving Outcomes for Lung Cancer and Diabetic Patients
Novel technologies have been developed with support from SBRI Healthcare funding.
New Way of Detecting Cancer
A new RNA test of blood platelets can be used to detect, classify and pinpoint the location of cancer by analysing a sample equivalent to one drop of blood.
Rapid, Portable Ebola Diagnostic
Scientists confirmed the efficiency of the novel Ebola detection method in field trials.
New, Better Test for Prostate Cancer
A study from Karolinska Institutet shows that a new test for prostate cancer is better at detecting aggressive cancer than PSA.
Blood Test Picks Out Prostate Cancer Drug Resistance
Scientists have developed a blood test that can identify key mutations driving resistance to a widely used prostate cancer drug, and identify in advance patients who will not respond to treatment.
Antibody Targets Key Cancer Marker
University of Wisconsin-Madison researchers have created a molecular structure that attaches to a molecule on highly aggressive brain cancer and causes tumors to light up in a scanning machine.
Key Piece of MRSA Vaccine Puzzle
New research funded by the Health Research Board and the Wellcome Trust has pinpointed immune cells that could be targeted by an MRSA vaccine.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos